Posts

Posted on

Elbit Systems Awarded $96 Million Contract to Supply a Rotary-Wing Mission Training Center to a European Country

PR Newswire

HAIFA, Israel, Nov. 29, 2020 /PRNewswire/ — Elbit Systems Ltd. (NASDAQ: ESLT, TASE: ESLT) (“Elbit Systems” or “the Company”) announced today that it was awarded a contract valued at approximately $96 million to supply a European country with a Rotary-Wing Mission Training Center (“Rotary-Wing MTC”) and support services to train its Air Force, Army and Navy helicopter pilots and crews. The contract will be performed over a nine-year period, with an option to extend the maintenance services for an additional 10-year period.

The Rotary-Wing MTC is a networked multi-platform, mission-oriented, helicopter training center that will provide multi-level training for helicopter pilots and aircrews across the customer’s Armed Forces. The new training center will enable realistic simulated tactical training using all of the helicopter’s systems in a wide variety of mission scenarios. The Rotary-Wing MTC draws on the unique technologies and accumulated operational experience of the Company’s fighter aircraft tactical mission training centers.


Yoram Shmuely,
General Manager of Elbit Systems’ Aerospace Division commented: “This contract highlights the growing importance that Armed Forces place on leveraging proven technologies to enhance readiness while reducing costs.”


About Elbit Systems

Elbit Systems Ltd. is an international high technology company engaged in a wide range of defense, homeland security and commercial programs throughout the world. The Company, which includes Elbit Systems and its subsidiaries, operates in the areas of aerospace, land and naval systems, command, control, communications, computers, intelligence surveillance and reconnaissance (“C4ISR”), unmanned aircraft systems, advanced electro-optics, electro-optic space systems, EW suites, signal intelligence systems, data links and communications systems, radios, cyber-based systems and munitions. The Company also focuses on the upgrading of existing platforms, developing new technologies for defense, homeland security and commercial applications and providing a range of support services, including training and simulation systems.

For additional information, visit: https://elbitsystems.com/, follow us on Twitter or visit our official Facebook, Youtube and LinkedIn Channels.



Company Contact:



IR Contact:

 


Joseph Gaspar, Executive VP & CFO


Ehud Helft

Tel:  +972-4-8316663


Kenny Green


[email protected] 


GK Investor Relations

Tel: 1-646-201-9246


Rami Myerson,
Director, Investor Relations


[email protected]

Tel: +972-77-2948984


[email protected]

 


David Vaaknin,
VP, Brand & Corporate Communications

Tel: +972-77-2946691


[email protected] 

This press release may contain forward–looking statements (within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended and the Israeli Securities Law, 1968) regarding Elbit Systems Ltd. and/or its subsidiaries (collectively the Company), to the extent such statements do not relate to historical or current facts. Forward-looking statements are based on management’s current expectations, estimates, projections and assumptions about future events. Forward–looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions about the Company, which are difficult to predict, including projections of the Company’s future financial results, its anticipated growth strategies and anticipated trends in its business.  Therefore, actual future results, performance and trends may differ materially from these forward–looking statements due to a variety of factors, including, without limitation: scope and length of customer contracts; governmental regulations and approvals; changes in governmental budgeting priorities; general market, political and economic conditions in the countries in which the Company operates or sells, including Israel and the United States among others; changes in global health and macro-economic conditions; differences in anticipated and actual program performance, including the ability to perform under long-term fixed-price contracts; changes in the competitive environment; and the outcome of legal and/or regulatory proceedings.  The factors listed above are not all-inclusive, and further information is contained in Elbit Systems Ltd.’s latest annual report on Form 20-F, which is on file with the U.S. Securities and Exchange Commission. All forward–looking statements speak only as of the date of this release. Although the Company believes the expectations reflected in the forward-looking statements contained herein are reasonable, it cannot guarantee future results, level of activity, performance or achievements. Moreover, neither the Company nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. The Company does not undertake to update its forward-looking statements.

Elbit Systems Ltd., its logo, brand, product, service and process names appearing in this Press Release are the trademarks or service marks of Elbit Systems Ltd. or its affiliated companies.  All other brand, product, service and process names appearing are the trademarks of their respective holders.  Reference to or use of a product, service or process other than those of Elbit Systems Ltd. does not imply recommendation, approval, affiliation or sponsorship of that product, service or process by Elbit Systems Ltd. Nothing contained herein shall be construed as conferring by implication, estoppel or otherwise any license or right under any patent, copyright, trademark or other intellectual property right of Elbit Systems Ltd. or any third party, except as expressly granted herein.

Cision View original content:http://www.prnewswire.com/news-releases/elbit-systems-awarded-96-million-contract-to-supply-a-rotary-wing-mission-training-center-to-a-european-country-301181303.html

SOURCE Elbit Systems Ltd.

Posted on

Colchicine shows promise as a treatment for at-home COVID-19 patients

Recruitment of participants in the COLCORONA phase 3 study likely to end in 2020

MONTREAL, Nov. 28, 2020 (GLOBE NEWSWIRE) — The Montreal Heart Institute (MHI) today announced that the COLCORONA clinical trial will continue to recruit non-hospitalized adult patients with COVID-19 as recommended by the independent data monitoring committee (DMC), following a second interim analysis.

“
With the
dramatic rise
in COVID-19 cases across the world, it is becoming even more critical that we continue to investigate treatments that can not only help those hospitalized with severe disease, but also those with less severe symptoms who are able to remain at home
”
,
said Dr. Jean-Claude Tardif, Director of the Research Center at MHI, Professor of Medicine at the University of Montreal, and COLCORONA pri
ncipal
investigator. “
We aim at completing patient recruitment
in this large study
within the next month and hope that colchicine will reduce the risk of
COVID-19
complications
.
”

COLCORONA is a contact-free, at-home, randomized, double-blind, placebo-controlled study run out of Canada, the United States, Europe, South America, and South Africa. It aims to determine if colchicine can reduce the risk of serious complications linked to COVID-19. This is one of the few current large-scale studies of COVID-19 in which non-hospitalized patients can participate. Participants and physicians interested in COLCORONA can call the hotline at 1-877-536-6837.

COLCORONA is coordinated by the Montreal Health Innovations Coordinating Center (MHICC) and funded by the Government of Quebec, the Bill & Melinda Gates Foundation and the National Heart, Lung, and Blood Institute (NHLBI) of the United States National Institutes of Health (NIH). CGI, Dacima and Pharmascience are also collaborators of COLCORONA.

The Montreal Heart Institute and its partners worldwide would like to thank all the investigators and the thousands of participants for their continued participation in the COLCORONA study.

For more information about the study, visit www.colcorona.net. 

About the Montreal Heart Institute

Founded in 1954, the Montreal Heart Institute constantly aims for the highest standards of excellence in the cardiovascular field through its leadership in clinical and basic research, ultra-specialized care, professional training, and prevention. It houses the largest research center in Canada, the largest cardiovascular prevention center in the country, and the largest cardiovascular genetics center in Canada. The Institute is affiliated with the University of Montreal and has more than 2000 employees, including 245 doctors and more than 85 researchers.

About the Montreal Health Innovations Coordinating Center (MHICC)

The Montreal Health Innovations Coordinating Center (MHICC) is a leading academic clinical research organization and an integral part of the Montreal Heart Institute (MHI). The MHICC possesses an established network of collaborators in over 4500 clinical sites in more than 35 countries. It has specific expertise in precision medicine, low-cost high-quality clinical trials, and drug repurposing.

About Pharmascience

Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec. With its head office located in Montreal and its 1,500 employees, Pharmascience Inc. is a private, full-service pharmaceutical company with deep roots in Canada, and whose global reach is growing, in part thanks to the distribution of its products in more than 60 countries. Ranked 56th among the top 100 Canadian investors in research and development (R&D) thanks to $43 million investment in 2018, Pharmascience Inc. is the 4th largest manufacturer of over-the-counter generic drugs in the country. www.pharmascience.com 

About CGI

Founded in 1976, CGI is one of the world’s largest information technology (IT) and management consulting firms. From hundreds of locations around the world, CGI offers a complete portfolio of services and solutions: strategic IT and management consulting services, systems integration services, intellectual property solutions as well as IT and business process management services in delegated mode. www.cgi.com/canada 

About Dacima

Founded in 2006, Dacima Software Inc. is a leading innovator in Electronic Data Capture (EDC) software for clinical research. Dacima’s EDC software, Dacima Clinical Suite, is a fully feature EDC software application with integrated modules for patient randomization (IWRS), supply management, ePRO, eDiary, medical coding and eConsent. Dacima’s flexible and highly configurable EDC platforms allow for the design of all types of study designs including clinical trials, patient registries, observational studies  and  web surveys  through an intuitive user-friendly web interface. www.dacimasoftware.com

Media Contacts:

Camille Turbide
[email protected]
+ 1 514-755-5354

 



Posted on

WaterMill Asset Management Refutes Ziopharm Oncology’s Desperate, Low-Road Smear Campaign

WaterMill Asset Management Refutes Ziopharm Oncology’s Desperate, Low-Road Smear Campaign

Highlights That Director Candidate Holger Weis Continues to Receive Public Endorsements From Highly-Respected Biotechnology Leaders, Including Former DemeRx Board Members

Notes That Mr. Weis’ Former Chairman at DemeRx Sees “no Merit to any of the Unsubstantiated Claims Referenced by Ziopharm”

Provides Point-by-Point Rebuttal to Address the False and Unsupported Attacks on Mr. Weis

Urges Shareholders to Look Past Ziopharm’s Distortions and Recognize That Mr. Weis has an Impeccable Track Record – With Zero Employment, Legal or Regulatory Blemishes

NEW YORK–(BUSINESS WIRE)–
WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation beneficially owns approximately 3.3% of the outstanding shares of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (“Ziopharm” or the “Company”), today responded to the low-road campaign that the incumbent Board of Directors (the “Board”) has apparently initiated in order to smear Holger Weis and misrepresent his more than six-year tenure at DemeRx Incorporated (“DemeRx”). WaterMill believes this seemingly underhanded stunt only reinforces the need for meaningful and urgent boardroom change. It is important to highlight that the incumbent Board’s desperate attack on Mr. Weis comes on the heels of Institutional Shareholder Services Inc. (“ISS”), a leading independent proxy voting advisory firm, recommending that Ziopharm shareholders vote for boardroom change on WaterMill’s WHITE consent card. ISS supports the addition of two WaterMill nominees (Jaime Vieser and Holger Weis) and the removal of two incumbents (Chairman Scott Tarriff and Director Elan Ezickson).

We want to highlight for shareholders that Mr. Weis has unimpeachable integrity and recently received several endorsements from highly-respected biotechnology and life science investors and leaders, including former DemeRx board members. Select endorsements are below.

  1. Henry Mellon, former Chairman of DemeRx, provided the following statement today:

    “I was chairman of the DemeRx board of directors for a significant portion of Holger’s tenure. He demonstrated integrity, professionalism and the highest degree of ethics at every turn – all in the interest of helping DemeRx succeed. Holger is a by-the-book corporate leader that shuns waste and prioritizes efficiency. In my view, there is no merit to any of the unsubstantiated claims referenced by Ziopharm on November 27.”

  2. Skip Clemmons, Managing Director of Stephens Inc. and former DemeRx director, recently stated:

    “I was on the board and Holger, while beginning our relationship as COO/CFO, also took on increasing responsibilities for operations and clinical trials leading to his eventual leadership of the company. In addition, Holger had the novel idea to combine opioids with a small amount of our compound to reduce the abuse liability of opioids, potentially slowing or preventing the onset of tolerance which leads to dependence. A major pharmaceutical company was eager to study this with our company. I found Holger to be fair, thoughtful, and professional in all things related to governance, compensation, and financial reporting. Further, his creative vision for additional applications created new clinical opportunities for us. Holger is a great leader, a generous colleague, a good man, and a solid contributor at the board level as well as management. I am proud to call him a friend and would be happy to work with him again.”

  3. James Barlow, President & Chief Executive Officer of ImmunoGenesis, Inc., recently stated:

    “I have a high regard for Holger’s deep expertise for operating Biotech companies. From his distinguished career as a C-suite Executive at numerous Biotechs, Holger […] would be a real asset in sharpening the operational focus at Ziopharm. He is refreshingly candid and has unquestioned integrity, which will allow him to be a strong, credible voice for change at the Company.”

  4. Hector J. Gomez MD PhD, Executive Chairman & Chief Medical Officer of GLG Pharma, LLC, recently stated:

    “[Holger has] a myriad of proficiencies that are invaluable for a pharma or biotech organization. I was amazed at the proficiency that he has with regulatory issues, clinical trial design, fundraising and just a general ‘solve-all-problems’ attitude. His relentless pursuit of success is admirable.”

In keeping with its apparent disregard for honest investor communication, the incumbent Board’s misleading press release on November 27th is full of cherry-picked quotes and completely unsubstantiated claims from a filing made by DemeRx during its 2018 bankruptcy. The incumbent Board’s press release does not acknowledge that Mr. Weis spent more than six years as an executive in good standing, enjoys the support of former DemeRx directors and was owed hundreds of thousands of dollars at the time of the organization’s bankruptcy. The press release also fails to acknowledge that DemeRx, which was under new leadership in 2018, was choosing to fight Mr. Weis rather than honor his claims as a creditor. The reality is that DemeRx’s founder and current chief executive officer, who was previously terminated by the board of directors in 2013, did not want to honor Mr. Weis’ claims once she was back in control.

We believe it is important to set the record straight now that Ziopharm is apparently trying to smear Mr. Weis:

  • Distortion #1: Ziopharm states that “a majority of shareholders executed written consents to remove Mr. Weis” from his positions at DemeRx.
    • The Reality: This statement is false. Mr. Weis was not a director of DemeRx and, therefore, could not be removed by written consent. Mr. Weis had a provision in his employment agreement that allowed him to resign for “good reason” if DemeRx’s founder and current chief executive officer ever returned. This is why Mr. Weis resigned on July 24, 2017.
  • Distortion #2: Ziopharm is apparently trying to mislead shareholders by repeating DemeRx’s unsupported claim that Mr. Weis made “inaccurate and misleading presentations” to his board of directors that resulted in “excessive remuneration.”
    • The Reality: Ziopharm is recycling false and unsubstantiated claims. Mr. Weis was evaluated by DemeRx’s board of directors for years, including its compensation committee and audit committee. He never made inaccurate and misleading statements to the board of directors. In addition, he was not in a position to influence what the board of directors deemed to be his appropriate compensation.
  • Distortion #3: Ziopharm is apparently trying to mislead shareholders again by citing DemeRx’s baseless contentions that Mr. Weis received “excessive compensation based on milestones never achieved” and “made unauthorized payments to himself.”
    • The Reality: Ziopharm is recycling more false and unsubstantiated claims. Mr. Weis submitted performance self-appraisals to the board of directors for its independent assessment throughout his more than six-year tenure. Any and all compensation received by Mr. Weis during his tenure at DemeRx was approved and authorized by the board of directors (which Mr. Weis was not a part of). Notably, Mr. Weis voluntarily worked without a salary and bonus throughout 2017 in order to help DemeRx allocate capital to other key business initiatives. He always acted in DemeRx’s best interest.
  • Distortion #4: Ziopharm apparently wants shareholders to believe Mr. Weis was responsible for millions of dollars of “waste” at DemeRx.
    • The Reality: Ziopharm is continuing to cite more false claims. Soon after joining DemeRx, Mr. Weis helped improve cost controls and he ultimately delivered tangible clinical progress on a very efficient budget. In fact, Mr. Weis was lauded for his cost efficiency by the board of directors (including members who continue to publicly support him today).
  • Distortion #5: Ziopharm wants shareholders to believe Mr. Weis was responsible for wasting funds on excessive patent-related legal fees at DemeRx.
    • The Reality: The claim being echoed by Ziopharm is baseless. Given that DemeRx had limited intellectual property at the onset of its development program, creating new patents was an important and essential strategic initiative towards building the business. The legal advisory work commissioned by Mr. Weis was regularly reviewed by the board of directors.

Robert Postma, principal and founder of WaterMill, concluded:

“Ziopharm’s incumbent Board never fails to disappoint when it comes to taking the low road. This attempt to smear Holger with baseless and unsubstantiated claims is just the latest instance of the incumbents’ desperation. It is clear to us that Scott Tarriff and his allies in the boardroom simply want to divert attention away from Ziopharm’s abysmal corporate governance, dismal business decisions, wasteful spending and value-destructive tailspin. Unfortunately for them, WaterMill will continue to make this contest about the issues that matter to shareholders. Holger, Jaime and I are committed to joining the Board and helping Ziopharm veer off its current path to financial ruin. WaterMill is also committed to Holger and encourages shareholders to focus on the facts pertaining to his robust credentials, quality endorsements and proven integrity.”

***

We urge Ziopharm shareholders to consent to all five proposals on the WHITE consent card today by signing, dating and returning it in the postage-paid envelope provided.Please vote each and every WHITE consent card you receive since you may own multiple accounts. If you have already voted a Green revocation card from Ziopharm, a later-dated vote on the WHITE consent card will revoke that vote.

December 11, 2020 is our goal for the submission of written consents. Effectively, this means that you have until December 11, 2020 to consent to the proposals.

You may only consent by voting the WHITE consent card. Please throw away all Green revocation cards you receive.

***

For Investors:

Saratoga Proxy Consulting

John Ferguson / Joe Mills, 212-257-1311

[email protected] / [email protected]

For Media:

Profile

Greg Marose / Charlotte Kiaie, 347-343-2999

[email protected] / [email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Professional Services Communications Other Professional Services Finance Consulting Banking Public Relations/Investor Relations

MEDIA:

Posted on

ROSEN, RESPECTED INVESTOR COUNSEL, Reminds Aurora Cannabis Inc. Investors of Important December 1 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm – ACB

NEW YORK, Nov. 28, 2020 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Aurora had significantly overpaid for previous acquisitions and experienced degradation in certain assets, including its production facilities and inventory; (2) Aurora’s purported “business transformation plan” and cost reset failed to mitigate the foregoing issues; (3) accordingly, it was foreseeable that Aurora would record significant goodwill and asset impairment charges; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 1, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1965.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        [email protected]
        [email protected]
        www.rosenlegal.com



Posted on

ROSEN, RESPECTED INVESTOR COUNSEL, Reminds Mesoblast Limited Investors of Important December 7 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm – MESO

PR Newswire

NEW YORK, Nov. 28, 2020 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mesoblast Limited (NASDAQ: MESO) between April 16, 2019 and October 1, 2020, inclusive (the “Class Period”), of the important December 7, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Mesoblast investors under the federal securities laws.

To join the Mesoblast class action, go to http://www.rosenlegal.com/cases-register-1923.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) comparative analyses between Mesoblast’s Phase 3 trial and three historical studies did not support the effectiveness of remestemcel-L for steroid refractory acute graft versus host disease (“aGVHD”) due to design differences between the four studies; (2) as a result, the U.S. Food and Drug Administration was reasonably likely to require further clinical studies; (3) as a result, the commercialization of remestemcel-L in the U.S. was likely to be delayed; and (4) as a result of the foregoing, defendants’ positive statements about Mesoblast’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 7, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1923.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      [email protected]
      [email protected]
      www.rosenlegal.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/rosen-respected-investor-counsel-reminds-mesoblast-limited-investors-of-important-december-7-deadline-in-securities-class-action-encourages-investors-with-losses-in-excess-of-100k-to-contact-firm–meso-301180895.html

SOURCE Rosen Law Firm, P.A.

Posted on

Two traveling Americans in search for a mojito in Cuba find so much more than what they were looking for

Yolanda Lopez chronicles her travel adventures in ‘Fuimos A Cuba’

RICHMOND, Calif., Nov. 28, 2020 (GLOBE NEWSWIRE) — Readers are invited to follow two American women on an adventure filled with fun and mishaps in Yolanda Lopez’s memoir, “Fuimos A Cuba” (published by Balboa Press).

 

“I wanted to share a side of Cuba not often written about,” the author states. “This trip was taken at a time when travel bans made it illegal for U.S. citizens to visit.”

 

As two clueless travelers who really did not know what they were embarking on at the time, Lopez and her friend, Emma, left San Francisco unprepared for the journey that lay ahead. What started as a travel to Cuba in search for a mojito ended up on a series of antics crisscrossing the entire island with an intrepid Spaniard they meet along the way. After detainment by the Cuban government, they go on to survive deadly jellyfish, a car crash, smoking a Cuban cigar and many other wild escapades. Their journey leads them to discover the real Cuba as remarkably beautiful island with its beaches, coastal cities, music and people.

 

When asked what she wants readers to take away from her memoir, Lopez says, “All travel requires a willingness to experience new things, to learn about other cultures, their values and their food.  Also, travel can be scary, but if you manage to keep your perspective and your sense of humor, you will be the better for it and you can have an adventure of a lifetime.”

 

The book is available for purchase at https://www.balboapress.com/en/bookstore/bookdetails/813947-fuimos-a-cuba. 

 

“Fuimos A Cuba”

By Yolanda Lopez

Hardcover | 6 x 9in | 108 pages | ISBN 9781982255886

Softcover | 6 x 9in | 108 pages | ISBN 9781982255862

E-Book | 108 pages | ISBN 9781982255879

Available at Amazon and Barnes & Noble

 

About the Author

An avid reader from a young age, Yolanda Lopez grew up in Southern California. She has an undergraduate degree from the University of California, Berkeley, and a juris doctor degree from the University of California, Davis. A longtime Bay Area resident, she is now retired. Lopez always wanted to travel from a young age, but did not begin her traveling adventures until middle age. Since then, she has taken many trips, regularly traveling to Oaxaca and San Miguel de Allende, Mexico, to celebrate the Day of the Dead. Lopez’s passion for reading and writing continues. She is working on her memoir.

Balboa Press, a division of Hay House, Inc. – a leading provider in publishing products that specialize in self-help and the mind, body, and spirit genres. Through an alliance with the worldwide self-publishing leader Author Solutions, LLC, authors benefit from the leadership of Hay House Publishing and the speed-to-market advantages of the self-publishing model. For more information, visit balboapress.com. To start publishing your book with Balboa Press, call 844-682-1282 today.

Attachment 



Marketing Services
Balboa Press
844-682-1282
[email protected]

Posted on

One woman tells her personal story of reincarnation when she was a high priestess in prehistoric Egypt more than 6,000 years ago

Anna-Marie Seidenschnur releases ‘One Life: An Autobiography of a High Priestess and Pharaoh in Ancient Egypt’

COPENHAGEN, Denmark, Nov. 28, 2020 (GLOBE NEWSWIRE) — “This story has been in the back of my mind for a very long time, and in recent years, fragments have appeared in my thoughts regularly. Gradually, I have felt the urge to follow the unusual life of this woman in its entirety and to write down the story,” Anne-Marie Seidenschnur states.

 

“One Life: An Autobiography of a High Priestess and Pharaoh in Ancient Egypt” (published by Balboa Press) is a narrative about a past life of Seidenschnur taking place approximately 6000 years ago in pre-dynastic Egypt when the country was at its prime and the priesthood enlightened. It is a soul memory of a woman who is trained to become a high priestess and the next pharaoh of the country together with her husband. Readers follow her from the planning of her new life till after death.

 

“The main character in this book is the daughter of pharaoh, Kelatep. We follow her life and family in an enlightened society. We meet her parents, the pharaoh Ptahhotep and Helatep, her uncle the high priest Ka-kefer, her cousin and husband Toto, and later their three children. They are important since they are all members of the royal family, all have high offices, and work endlessly and selflessly for God, the light and Egypt,” Seidenschnur says.

 

“One Life: An Autobiography of a High Priestess and Pharaoh in Ancient Egypt” is an example of a selfless, fulfilled and perfect life in a near perfect society of a mysterious and ancient Egypt that has the highest spiritual values. “We need this more than ever at this present time.  I hope this story will bring hope and inspiration,” Seidenschnur concludes. For more details about the book, please visit https://www.balboapress.com/en/bookstore/bookdetails/782422-one-life

 

“One Life: An Autobiography of a High Priestess and Pharaoh in Ancient Egypt”

By Anne-Marie Seidenschnur

Hardcover | 6 x 9in | 284 pages | ISBN 9781982252892

Softcover | 6 x 9in | 284 pages | ISBN 9781982252878

E-Book | 284 pages | ISBN 9781982252885

Available at Amazon and Barnes & Noble

 

About the Author

Anne-Marie Seidenschnur is a medical doctor and graduated from the University of Copenhagen, Denmark, in 1987. She has specialized in general medicine and practices in Denmark. She was raised in a spiritually interested family and began meditating at the early age of 14. The spiritual interest has stayed with her all through life.

Balboa Press, a division of Hay House, Inc. – a leading provider in publishing products that specialize in self-help and the mind, body, and spirit genres. Through an alliance with the worldwide self-publishing leader Author Solutions, LLC, authors benefit from the leadership of Hay House Publishing and the speed-to-market advantages of the self-publishing model. For more information, visit balboapress.com. To start publishing your book with Balboa Press, call 844-682-1282 today.

Attachment 



Marketing Services
Balboa Press
844-682-1282
[email protected]

Posted on

Malamateniah Koutsada says ‘a migrant can dream’ in her new book

How she came out of the struggles as told in ‘. . . But I Promised God’

MELBOURNE, Australia, Nov. 28, 2020 (GLOBE NEWSWIRE) — A painful past made Malamateniah Koutsada be determined to reach her dreams. “. . . But I Promised God” (published by Xlibris AU in January 2019), which receives a new marketing campaign tells others to follow their dreams. The memoir tells of her struggles as she experienced both domestic violence and the Greek Civil War until she became successful in real estate. Here is an extract taken from the book:

 

Some of us use those obstacles as stepping stones to get across to the other side to do bigger and better things. Others use them as obstacles to stay back, do nothing other than blame others, and talk about their bad luck. I don’t want to be one of them. I want to see myself as a victor over life’s battles, not as a victim.

 

Koutsada shares her experience during the Greek civil war, by the time she migrated to Australia and her failed marriage. Through this book, she wants her family to learn from her and understand the actions she was taking.

 

“I want my children and grandchildren to know who I am and why I behaved the way I did, so that they can understand me and forgive my mistakes. I want to help other parents avoid the mistakes I have made bringing up my children,” she says.

 

“. . . But I Promised God” is a story of triumph over adversity. She wants her readers to learn that one can forgive without bitterness. To know more about the book, visit https://www.amazon.com/but-Promised-God-ebook/dp/B07PXJJH54/ref=sr_1_1?keywords=9781984504562&qid=1573611327&s=books&sr=1-1.

 

“. . . But I Promised God”

By Malamateniah Koutsada

Hardcover | 6×9 in | 442 pages | ISBN 9781984504562

Softcover | 6×9 in | 442 pages | ISBN 9781984504548

E-Book | 442 pages | ISBN 9781984504555

Available at Amazon and Barnes & Noble

 

About the Author

Malamateniah Koutsada lives in Melbourne and is a psychiatric nurse past her retiring age. She is still working in a psychiatric unit and enjoys her work, and hopes to be working for some time yet.

Xlibris Publishing Australia, an Author Solutions, LLC imprint, is a self-publishing services provider dedicated to serving Australian authors. By focusing on the needs of creative writers and artists and adopting the latest print-on-demand publishing technology and strategies, we provide expert publishing services with direct and personal access to quality publication in hardcover, trade paperback, custom leather-bound and full-color formats. To date, Xlibris has helped to publish more than 60,000 titles. For more information, visit xlibrispublishing.com.au or call 1-800-844-927 to receive a free publishing guide.

Attachment 



Marketing Services
XlibrisAU
1-800-844-927
[email protected]

Posted on

A young journalist’s story rocks the world to its core and spirals her life onto an unimaginable journey of hope and despair

Peter Breally announces the release of ‘Demography Day’

CANNONVALE, Australia, Nov. 28, 2020 (GLOBE NEWSWIRE) — Peter Breally has written poetry and short stories for yachting publications. Inspired by a sailing trip to the remote Cocos Keeling Islands, he now releases his first full-length novel titled “Demography Day” (published by Xlibris AU).

           

A young journalist expecting her first child attends the prenatal clinic in Gladstone Australia where she lives and by a quirk of fate discovers that all women the world over have stopped falling pregnant for no explicable reason. The story that she writes for her newspaper rocks the world to its core and spirals her personal life onto an unimaginable journey of hope and despair.

 

“This book is unique in the way that it takes readers into a journey like no other. Readers will be intrigued from page one, wondering where this tale is going,” Breally says. “It also touches issues of our modern world such as over population, species decline and the loss of cultural values.”

 

When asked what he wants readers to take away from his writing of this novel, Breally replies, “An awareness of the issues we face as inhabitants of an overcrowded planet.” For more details about this book, please visit https://www.amazon.com/Demography-Day-Peter-Breally/dp/1664101160.

 

“Demography Day”

By Peter Breally

Hardcover | 6 x 9in | 466 pages | ISBN 9781664101173

Softcover | 6 x 9in | 466 pages | ISBN 9781664101166

E-Book | 466 pages | ISBN 9781664101159

Available at Amazon and Barnes & Noble

 

About the Author

Peter Breally and his wife have chosen to retire on their coastal property in Queensland after many years of living on their yacht and traveling from one project to the next in the heavy construction industry.

 

Xlibris Publishing Australia, an Author Solutions, LLC imprint, is a self-publishing services provider dedicated to serving Australian authors. By focusing on the needs of creative writers and artists and adopting the latest print-on-demand publishing technology and strategies, we provide expert publishing services with direct and personal access to quality publication in hardcover, trade paperback, custom leather-bound and full-color formats. To date, Xlibris has helped to publish more than 60,000 titles. For more information, visit xlibrispublishing.com.au or call 1-800-844-927 to receive a free publishing guide.

Attachment 



Marketing Services
XlibrisAU
1-800-844-927
[email protected]

Posted on

A tale of action, adventure and intrigue awaits readers in new historical fiction

A.W. Bennett and Ben Lewis announce the publication of ‘The Battle of Jettena Junction’

SORELL, Australia, Nov. 28, 2020 (GLOBE NEWSWIRE) — A.W. Bennett and Ben Lewis delights lovers of history and fiction with the release of “The Battle of Jettena Junction” (published by Balboa Press AU). This novel tells a story filled action, adventure and intrigue.

 

The Union had turned the tide of the war by the summer of 1863. The Confederate States were in total disarray following the devastating loses at Gettysburg and Vicksburg in the summer of 1863. Adding to the insults, nature had delivered a devastating drought in the south. The South needed a miracle and what better one than to kidnap President Abraham Lincoln on route from Washington to Gettysburg where he was to speak on behalf of the fallen.

 

“‘The Battle of Jettena Junction’ is a remarkable work. This intriguing combination of fiction work and history textbook subverts and reverses the expectations of historical fiction, using plot as the backdrop for history rather than history as the backdrop for the plot — a history book with a dash of fiction rather than a fiction book with a dash of history,” Bennett guarantees.

 

To purchase a copy, visit https://www.balboapress.com/en-au/bookstore/bookdetails/809467-the-battle-of-jettena-junction.

 

“The Battle of Jettena Junction”

By A.W. Bennett and Ben Lewis

Softcover | 7.5 x 9.25in | 522 pages | ISBN 9781504323055

E-Book | 522 pages | ISBN 9781504323192

Available at Amazon and Barnes & Noble

 

About the Author

As a young child, A.W. Bennett has always had a good imagination and he loves writing.  He wrote many stories on local people — turning fact into fiction — and he kept everyone entertained on long bus “sporting trips” by reading these stories on the way home from sporting activities. During the early 1990s, he decided to take a break, but, somehow, his love of American western stories and the Civil War kept dragging him back. Just after he moved down to Tasmania in 2011, he was watching a documentary on the history channel regarding President Abraham Lincoln’s journey from Washington to Gettysburg to present his famous “Gettysburg Address.” He then began researching the Civil War and those who participated in the conflict. This eventually led to “The Battle of Jettena Junction,” which was read over and proofread by Ben Lewis.

Balboa Press Australia is a division of Hay House, Inc., a leading provider in publishing products that specialise in self-help and the mind, body and spirit genre. Through an alliance with the worldwide self-publishing leader Author Solutions, LLC, authors benefit from the leadership of Hay House Publishing and the speed-to-market advantages of the Author Solutions self-publishing model. For more information or to start publishing today, visit balboapress.com.au/ or call 1-800-844-925.

Attachments 



Marketing Services
Balboa Press AU
1-800-844-925
[email protected]